IGF-1 LR3 is a modified synthetic variant of Insulin-like Growth Factor 1 featuring an arginine extension (R3) that prolongs its half-life to 20–30 hours by bypassing endogenous binding proteins. It is researched for its direct pathways in muscle hyperplasia, tissue repair, and systemic anabolism. This investigational substance is not FDA-approved and is classified strictly for research purposes.